Breyanzi access in Nepal: the DDA named-patient pathway
How Nepali patients with relapsed or refractory large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma legally access Breyanzi (lisocabtagene maraleucel), a CD19-directed CAR-T cell therapy, through the Department of Drug Administration named-patient pathway.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Breyanzi in Nepal
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Breyanzi (lisocabtagene maraleucel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved by the US Food and Drug Administration in February 2021. The label has expanded across diffuse large B-cell lymphoma and other large B-cell lymphomas (initially third-line, then second-line after TRANSFORM in June 2022), chronic lymphocytic leukemia and small lymphocytic lymphoma (March 2024), follicular lymphoma (May 2024), and mantle cell lymphoma (May 2024). The product is manufactured by Bristol-Myers Squibb. TRANSCEND data report overall response rates of approximately 73 percent with 53 percent complete response in heavily pretreated populations. Breyanzi is not registered with Nepal's Department of Drug Administration (DDA), and access for a Nepali patient runs through the personal-use import permit combined with autologous cell collection arranged at a CAR-T-authorised center.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why Nepali patients ask about Breyanzi
Nepal's tertiary oncology infrastructure is concentrated at Bir Hospital, Bhaktapur Cancer Hospital, B.P. Koirala Memorial Cancer Hospital in Bharatpur, Tribhuvan University Teaching Hospital in Kathmandu, Patan Hospital, and the major private hospitals (Norvic International Hospital, Grande International Hospital, HAMS Hospital, Vayodha Hospital). Families arrive at the Breyanzi question after exhausting the conventional aggressive B-cell lymphoma sequence, and the realistic conversation is about cross-border infusion almost universally.
The DDA named-patient pathway for Breyanzi
Nepal's framework for unregistered-medicine import runs through the Department of Drug Administration (DDA) under the Drugs Act 1978 and DDA regulations. The personal-use import permit is available where a DDA-licensed physician documents clinical necessity. For autologous CAR-T cell therapy, the DDA permit can issue in principle, with operational complexity in infusion-center identification and cell shipment chain of custody. Nepali patients are often referred to Indian tertiary centers, in which case the regulatory permit is sometimes coordinated through the receiving Indian center's CDSCO Rule 36 framework rather than DDA.
A complete DDA application includes the clinical justification letter, the physician's Nepal Medical Council registration, the destination infusion center identification, the leukapheresis collection plan, the BMS manufacturing slot, and the post-infusion monitoring plan. We give you a written timeline estimate for your case before you commit.
Where Breyanzi cases are infused for Nepali patients
Nepal does not currently operate a domestic CAR-T-authorised infusion center. Nepali families pursuing Breyanzi typically infuse at an Indian academic medical center where CAR-T capability has been stood up (Bir Hospital, Tribhuvan University Teaching Hospital, B P Koirala Memorial Cancer Hospital, Civil Service Hospital, and Grande International Hospital), a US academic medical center (MD Anderson, Memorial Sloan Kettering, Dana-Farber, City of Hope, Moffitt), or a European reference center. India-route is operationally and culturally easier for many Nepali families. Leukapheresis collection can be performed in Nepal at a qualified Kathmandu center or in India.
Real cost picture for Breyanzi cases
Medicine price: quote on request. You get a written quote for your case before you commit. Cash-pay is the operating assumption.
Typical timeline for Breyanzi in Nepal
We give you a written timeline estimate for your case before you commit. Manufacturing-failure rate of approximately 5 to 10 percent is a real operational risk.
What your physician needs to provide
For a Nepali hematologist coordinating a Breyanzi case, the clinical justification letter documents the lymphoma subtype with cell-of-origin, MYC and BCL2/BCL6 status where relevant, prior line-of-therapy summary, current disease burden including imaging, performance status, comorbidity profile, fitness for lymphodepleting chemotherapy, cardiac and pulmonary baseline, and bridging therapy plan. The physician's Nepal Medical Council number, the institutional affiliation, and the receiving Indian or US center referral letter complete the paperwork.
Common questions about Breyanzi in Nepal
Is the India-route the realistic option? For most Nepali families, yes. India operates established CAR-T programs at multiple centers.
Can the collection happen in Nepal? Leukapheresis at a qualified Kathmandu center is operationally feasible under chain-of-custody arrangements; collection at the receiving Indian center is simpler.
What is the alternative if CD19 CAR-T is not feasible? Alternatives include the bispecific antibody class (epcoritamab, glofitamab, mosunetuzumab), tafasitamab plus lenalidomide, polatuzumab vedotin combinations, loncastuximab tesirine, and clinical trial enrollment.
What about Yescarta or Kymriah? Both are alternative CD19 CAR-Ts. Indian centers may have differential access to specific products.
How does long-term follow-up work? CAR-T REMS requires ongoing monitoring. The patient returns to Nepal with a structured handoff package to the local hematologist.
Where Reserve Meds fits in Breyanzi cases
Reserve Meds is a US-based digital health company. For Breyanzi cases originating in Nepal, our role focuses on US-side sourcing where the US-route is chosen, infusion-center identification and intake coordination, leukapheresis collection logistics, DDA documentation packet for your physician, international travel and accommodation coordination, and a single point of contact. Where the case routes to India, we coordinate with the receiving Indian center on the operational handoff.
Next step
If your Nepali hematologist is considering Breyanzi, the next step is a short intake. We confirm eligibility within one business day.
Reserved for you.